CLINICAL ACTIVITY SCORES ARE IMPROVING IN PATIENTS WITH MILD THYROID-ASSOCIATED ORBITOPATHY RECEIVING ADJUVANT SELENIUM SUPPLEMENTATION
The essential trace element selenium (Se) exerts complex effects on the endocrine and immune systems, partly due to its antioxidant capacity. The importance of an optimal Se intake has been established in autoimmune thyreoiditis. A recently published study reported beneficial results in Se supplemented patients with mild Graves’ orbitopathy. Eight female patients with mild Graves’ orbitopathy and three female patients with mild orbitopathy based on Hashimoto thyreoiditis participated in the study. The status of the orbita was registered at the beginning of the study and one-six months thereafter both according to the scores recommended by the American Thyroid Association (ATA) and clinical activity scores (CAS). The patients were treated according to their thyroid hormone status, their antibody results and their CAS. Moreover, they received adjuvant Se as 100 or 200 μg sodium-selenite. Serum Se concentrations were measured before Se supplementation was implemented and 1-6 months after the beginning of treatment. ATA scores improved in 10 patients and worsened slightly in one female patient. CAS improved in all study participants. Mean Se concentrations were 75.08±11.55μg/l before supplementation was started and 91.35±17.37μg/l one-eight months later (p<0.05). At the beginning of the study, the majority of patients exhibited elevated antibody levels. After conventional treatment and adjuvant Se supplementation, antibody levels decreased or reached the normal range (except in the case of one patient).
- There are currently no refbacks.
*********************** European Chemical Bulletin *******************